Wellcome Trust

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.

data.org seeks to democratize and reimagine the use of data science to tackle society’s greatest challenges and improve lives across the globe. Our current initiatives aim to advance inclusive growth, build capacity, mitigate and adapt to climate change and fight pandemics.

Generate Capital, Inc. is a specialty finance company focused on building, owning, and operating sustainable infrastructure to provide affordable and reliable resource solutions. Founded in 2014 and headquartered in San Francisco, California, the company finances assets across various sectors, including energy storage, solar, energy efficiency, mobility, and water resources. Generate Capital offers a range of financial products, including asset-backed lending, project finance, and customized financing solutions. The company collaborates with project developers, technology manufacturers, and contractors to facilitate the deployment of scalable businesses in renewable energy and sustainability, enabling its partners to generate revenue and enhance their operations.

Oxitec is a biotechnology company focused on developing environmentally friendly solutions for controlling insect pests that transmit diseases and damage crops. Founded in 2002 and based in Oxford, United Kingdom, the company utilizes proprietary technology derived from research at the University of Oxford. This technology enhances the traditional Sterile Insect Technique (SIT) by integrating genetics and molecular biology, making it more cost-effective and safe for a wider range of insect pests. Oxitec offers various genetically modified strains, including Aedes aegypti and Aedes albopictus, which target disease-carrying mosquitoes, as well as strains for agricultural pests like the Diamondback moth and Pink bollworm. These innovations aim to provide targeted, non-toxic, and scalable pest control solutions that protect public health, agricultural productivity, and ecosystems. The company also operates a mosquito production facility in Piracicaba, Brazil, contributing to its global efforts in pest management.

TAE Technologies is leveraging proprietary science and engineering to tackle the world’s biggest challenges. Their core mission is to create a new source of clean energy – one that’s powered by nature’s own processes and produces no harmful byproducts. Their groundbreaking work has led to industry-wide advances in accelerator and plasma physics, and acted as a catalyst for adjacent innovations based on their results. With 20 years of focused research, TAE Technologies is on a purposeful path to commercial fusion energy and pioneering sustainable solutions for a better tomorrow.

ThinkSono Ltd is a London-based company that specializes in developing software for diagnosing deep vein thrombosis (DVT) at the point of care. Founded in 2016, the company has created an automatic diagnostic system that utilizes deep learning technologies. This innovative system guides healthcare professionals in placing a portable ultrasound scanner on the skin to capture images of underlying blood vessels. The software then analyzes these images, allowing doctors to make a DVT diagnosis within ten minutes, significantly enhancing the efficiency of patient care.

Transformative AI Limited, established in 2016 and based in London, United Kingdom, focuses on developing a healthcare platform that utilizes a patent-pending algorithm to predict the onset of sudden cardiac arrest. This innovative technology enables the collection and translation of clinical data into real-time predictive assessments, allowing patients and healthcare providers to identify life-threatening medical events before they occur. By providing advanced warnings, the platform empowers healthcare professionals to prepare for timely interventions, ultimately aiming to enhance patient outcomes and promote longer, healthier lives.

Verne Global, Inc. specializes in delivering computing solutions within an optimized environment, focusing on colocation and HPC-as-a-Service offerings, along with DGX-Ready Hosting for data centers. Founded in 2006 and based in Arlington, Virginia, the company operates a 45-acre data center campus in Keflavik, Iceland, which began operations in 2012. This facility was designed to address the rising costs and availability challenges of power in the data center industry while prioritizing environmental sustainability. The campus exclusively utilizes renewable energy sources and is strategically located between Europe and North America, enabling it to provide global customers with affordable, carbon-neutral power. Verne Global serves various industries, including artificial intelligence, earth sciences, engineering, financial services, life sciences, and scientific research, making it a key player in the energy-efficient data solutions market.

Mologic Ltd. is a diagnostic product developer based in Thurleigh, United Kingdom, founded in 2003. The company specializes in creating innovative solutions for the research market, focusing on areas such as clinical research, diagnostic development, and microbial physiology. Mologic offers a range of products, including lateral flow kits for human Alpha-1 antitrypsin, desmosine ELISA kits for urine assays, and the fMLP assay kit for measuring fMLP in human urine. In addition to its product lineup, Mologic provides services such as assay and reagent development, clinical evaluation studies, and the creation of high-performance antibodies targeting challenging biological entities. The company was established by Paul and Mark Davis, driven by a mission to enhance healthcare and education, thereby improving patient care and quality of life.

Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, focused on developing innovative vaccination and cancer immunotherapy solutions utilizing synthetic biology. The company specializes in microbial genetics products that aim to generate robust immune responses, including mucosal, systemic, and cellular immunity. Prokarium's product portfolio includes vaccines for infectious diseases such as Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever, as well as Vaxonella, which facilitates the delivery of antigens through the gastrointestinal tract to stimulate immune responses. The company aims to transform the oncology landscape by developing immunotherapy treatments, particularly targeting solid tumors and bladder cancer, through a synthetic biology platform designed to create living cures. Founded in 2007, Prokarium strives to enhance the safety and effectiveness of vaccines and immunotherapies in combating various diseases.

Kineta, Inc. is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing immunology-based therapies targeting oncology, neuroscience, and virology. The company is advancing several innovative treatments, including KCP-506, a non-opioid therapeutic for chronic pain, and LHF-535, an oral antiviral for Lassa and other arenaviruses, which works by inhibiting viral entry and replication. Additionally, Kineta is exploring RIG-I and VISTA drug development programs aimed at reprogramming the immune system to combat cancer. Founded in 2007, Kineta has established strategic partnerships with major pharmaceutical firms to enhance its research and development efforts.

A biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. It antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines and a variety of other product candidates for emerging viruses.

Karuna Pharmaceuticals, Inc. engages in development of drugs for the treatment of schizophrenia. The company was incorporated in 2009 and is based in Boston, Massachusetts.

Karuna Pharmaceuticals, Inc. engages in development of drugs for the treatment of schizophrenia. The company was incorporated in 2009 and is based in Boston, Massachusetts.

Karuna Pharmaceuticals, Inc. engages in development of drugs for the treatment of schizophrenia. The company was incorporated in 2009 and is based in Boston, Massachusetts.

PredictImmune Ltd is a company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Its primary product, PredictSURE IBD, is designed to guide treatment options for patients with Inflammatory Bowel Disease, including Crohn's disease and ulcerative colitis. This innovative test utilizes a small blood sample to accurately identify patients at the time of diagnosis who are at risk for severe, relapsing disease. By providing essential information regarding long-term clinical prognosis, the test supports healthcare professionals in determining personalized treatment plans, particularly the timely use of biologics therapy. PredictImmune's approach is recognized as beneficial by physicians, patients, and payors, as it enhances the management of Inflammatory Bowel Disease and improves patient outcomes.

DoorDash, Inc. is a logistics platform that connects merchants, consumers, and delivery personnel in the United States and internationally. Founded in 2013 and headquartered in San Francisco, the company facilitates restaurant food delivery services, allowing customers to order from local and national eateries through its app. DoorDash operates a marketplace that helps merchants enhance their online presence, manage customer acquisition, and streamline delivery processes. In addition to food delivery, the platform serves various businesses, including grocery, retail, and pet supply stores. The company has expanded its services into Europe through the acquisition of Wolt in 2022, reinforcing its commitment to building last-mile delivery infrastructure and transforming local commerce.

CorInnova Incorporated, founded in 2004 and based in Houston, Texas, specializes in device-based therapies aimed at treating congestive heart failure. The company is known for its innovative non-blood-contacting soft robotic cardiac assist device, which has the potential to significantly increase the number of heart failure patients eligible for life-saving device therapies. By focusing on advanced technological solutions, CorInnova seeks to improve outcomes for individuals suffering from this serious condition.

Instacart is a grocery delivery service that enables customers to receive groceries and home essentials at their doorstep, often within an hour. Founded in 2012 and headquartered in San Francisco, Instacart offers a wide selection of over 500,000 items from various local grocery stores, including well-known retailers such as Safeway, Whole Foods, and Costco. Customers can conveniently combine products from multiple stores into a single order, making the shopping experience more efficient. The company connects customers with individual shoppers who fulfill their orders, allowing for a personalized service. Instacart has garnered significant funding from various prominent investment firms, supporting its growth and expansion in the competitive grocery delivery market.

ResearchGate GmbH operates an online professional network specifically designed for scientific researchers globally. Founded in 2008 in Berlin, Germany, by Dr. Ijad Madisch, Dr. Sören Hofmayer, and Horst Fickenscher, the platform facilitates the discovery and sharing of scientific knowledge, allowing users to access publications, publish data, and obtain citation statistics for their work. Researchers can connect with colleagues, co-authors, and specialists, fostering collaboration and addressing research-related inquiries. In addition to its web platform, ResearchGate offers mobile applications, further enhancing accessibility for its over 14 million members. The company aims to promote open science and drive progress in research through its various tools and features.

Exonate Limited is a private biotech company based in Duxford, United Kingdom, specializing in the discovery and development of small molecule drugs aimed at modulating alternative messenger RNA splicing for ophthalmological applications. Founded in 2013, the company emerged from the University of Nottingham and is focused on addressing retinal vascular diseases, particularly diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD). Exonate's lead program utilizes small molecule inhibitors that selectively target serine/threonine-protein kinase 1 to inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) splice variants. This innovative approach aims to improve therapeutic outcomes and offers a potential alternative to current treatment methods, such as anti-VEGF injections and laser surgery. With a preclinical candidate drug already nominated, Exonate is advancing its research through regulatory toxicology and safety pharmacology studies to facilitate clinical evaluation. The company is backed by an experienced management team with expertise in medicine and drug development.

Kymab Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of human monoclonal antibody therapeutics. Utilizing its proprietary Kymouse platform, Kymab captures the diversity of the human immune system's B lymphocyte component to generate biopharmaceuticals targeting both established and novel drug targets. The company's therapeutic focus spans immuno-oncology, immunology, and other opportunistic areas. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to enhance its research and development efforts. Founded in 2009, Kymab continues to advance its pipeline of monoclonal antibody candidates aimed at addressing significant medical needs.

Phononic, Inc. specializes in the design, prototyping, and manufacturing of innovative cooling and heating solutions, focusing on solid-state technology. Founded in 2008 and based in Durham, North Carolina, the company develops thermoelectric devices and heat pumps that replace traditional compressor technology in various applications. Its products are utilized for electronics cooling in sectors such as optoelectronics and high-performance computing, as well as in healthcare, residential, and commercial refrigeration. Phononic's thermoelectric chips, made from bismuth telluride, offer sustainable and efficient temperature control without the use of toxic refrigerants, making them suitable for industries that require precise temperature management while reducing energy consumption. The company's approach aims to deliver smart and sustainable solutions for diverse climate control needs.

Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, specializing in the development of medical treatments for atrial fibrillation (AF), the most common type of cardiac arrhythmia. Founded in 2011, the company focuses on creating SK channel inhibitors, which are designed to be safe and tolerable options for patients. These drugs work by inhibiting specific ion channels in heart cells that are crucial for generating the electrical signals that regulate the heart's rhythm. Acesion Pharma aims to provide effective chronic treatments that prevent the recurrence of AF and help maintain a normal heart rhythm.

Pearl specializes in aftermarket automotive devices that enhance driver safety through advanced driver assistance features. The company's flagship product, Pearl RearVision, is a rear view camera that attaches to a vehicle's license plate, allowing users to view the feed on their smartphones. This system provides audio-visual alerts for obstacle detection, helping drivers avoid accidents. By leveraging technologies foundational to autonomous vehicles, Pearl makes these essential safety features accessible to a broader range of consumers, improving the overall driving experience and promoting road safety.

DoorDash, Inc. is a logistics platform that connects merchants, consumers, and delivery personnel in the United States and internationally. Founded in 2013 and headquartered in San Francisco, the company facilitates restaurant food delivery services, allowing customers to order from local and national eateries through its app. DoorDash operates a marketplace that helps merchants enhance their online presence, manage customer acquisition, and streamline delivery processes. In addition to food delivery, the platform serves various businesses, including grocery, retail, and pet supply stores. The company has expanded its services into Europe through the acquisition of Wolt in 2022, reinforcing its commitment to building last-mile delivery infrastructure and transforming local commerce.

Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. Our initial focus is on developing therapies to reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve. Quethera is working alongside world leaders in the glaucoma field to design clinical trials capable of examining the efficacy and safety of novel therapies in patients who lose parts of their visual field at an accelerated rate (fast-progressors). The company has expertise in gene therapeutic design and development sufficient to progress its pipeline through preclinical testing and into clinical development.

Mucosis B.V. is a clinical-stage biotechnology company based in the Netherlands, focused on developing innovative mucosal vaccines that can be administered needle-free through the nose or mouth. Its lead product candidate, SynGEM, is an intranasal vaccine aimed at preventing respiratory syncytial virus (RSV) infection. The company's vaccines utilize the patented Mimopath technology, which facilitates a more natural immune response and offers broad protection against infectious diseases. This approach has shown promise in both animal and human studies, particularly with the FluGEM vaccine candidate, by targeting the innate immune system through Toll-like receptor 2 (TLR2) to activate the adaptive immune response. Mucosis aims to address various infectious diseases, including RSV, pneumococci, and influenza.

MediSieve Ltd. is a London-based medical device company that specializes in developing Magnetic Blood Filtration (MBF) technology for the treatment of blood-borne diseases. The company’s innovative device employs a magnetic filter to remove infected blood cells, making it applicable for conditions such as malaria, leukemia, and sepsis. MediSieve’s system operates by circulating a patient’s blood through an external loop, where targeted magnetic particles bind to specific disease-related targets. The blood is then filtered through a magnetic device that captures these particles and their attached targets, allowing the remainder of the blood to return to the patient without contamination. Founded in 2014 and located at the Imperial Incubator in White City, London, MediSieve has dedicated facilities for product development and validation, including capabilities for various blood testing methods.

Elastagen Pty Ltd., a clinical stage medical company, produces and sells products based on the human protein tropoelastin. The company offers injectable dermoaesthetic products, stretch mark products, scar revision and wound healing products, and sealant and osteoskeletal products for applications areas, including skin rejuvenation, scar remodeling, and tissue repair. It sells its products through online orders. Elastagen Pty Ltd. was founded in 2003 and is based in Eveleigh, Australia with production operations in Europe; and clinical operations in the United Kingdom. As of April 6, 2018, Elastagen Pty Ltd. operates as a subsidiary of Allergan plc.

Klarna is a payment solutions provider that specializes in eCommerce, offering services for both consumers and merchants in several countries, including Sweden, Germany, Austria, Switzerland, and Norway. Founded in 2005 and headquartered in Stockholm, Klarna enables shoppers to select how and when to pay for their purchases through a variety of options such as card payments, direct banking, and installment plans. The company is particularly known for its "buy now, pay later" model, which allows consumers to finance retail purchases without interest over time. For merchants, Klarna provides a comprehensive suite of services that includes technology solutions, credit risk management, and customer administration, facilitating a streamlined shopping experience both online and in-store.

Antabio SAS is a biopharmaceutical company based in Labège, France, focused on developing drugs to combat antibiotic-resistant bacterial infections. Established in 2009, the company specializes in creating inhibitors that target bacterial metalloenzymes to restore the efficacy of existing antibiotics against critical pathogens. Among its key developments are a Metallo Beta-Lactamase inhibitor designed to enhance carbapenem treatment, a Serine Beta-Lactamase inhibitor with broad coverage against key enzymes, and Pseudomonas Elastase inhibitors, which aim to reduce the frequency and severity of exacerbations in patients with Pseudomonas infections. Antabio's innovative approach addresses significant unmet medical needs in the fight against nosocomial infections, particularly those caused by drug-resistant bacteria.

Nabriva Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious bacterial infections. The company's lead product, lefamulin, is a semi-synthetic pleuromutilin antibiotic designed to treat community-acquired bacterial pneumonia and acute bacterial skin infections. It is currently undergoing clinical trials for additional applications, including pediatric infections, sexually transmitted infections, osteomyelitis, and prosthetic joint infections. Nabriva is also advancing CONTEPO, an epoxide antibiotic aimed at treating complicated urinary tract infections, and it is in clinical trials for peri-operative prophylaxis. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva Therapeutics has evolved from its earlier identity as a research institute focused on antibiotic development.

DoorDash, Inc. is a logistics platform that connects merchants, consumers, and delivery personnel in the United States and internationally. Founded in 2013 and headquartered in San Francisco, the company facilitates restaurant food delivery services, allowing customers to order from local and national eateries through its app. DoorDash operates a marketplace that helps merchants enhance their online presence, manage customer acquisition, and streamline delivery processes. In addition to food delivery, the platform serves various businesses, including grocery, retail, and pet supply stores. The company has expanded its services into Europe through the acquisition of Wolt in 2022, reinforcing its commitment to building last-mile delivery infrastructure and transforming local commerce.

Verne Global, Inc. specializes in delivering computing solutions within an optimized environment, focusing on colocation and HPC-as-a-Service offerings, along with DGX-Ready Hosting for data centers. Founded in 2006 and based in Arlington, Virginia, the company operates a 45-acre data center campus in Keflavik, Iceland, which began operations in 2012. This facility was designed to address the rising costs and availability challenges of power in the data center industry while prioritizing environmental sustainability. The campus exclusively utilizes renewable energy sources and is strategically located between Europe and North America, enabling it to provide global customers with affordable, carbon-neutral power. Verne Global serves various industries, including artificial intelligence, earth sciences, engineering, financial services, life sciences, and scientific research, making it a key player in the energy-efficient data solutions market.

Phononic, Inc. specializes in the design, prototyping, and manufacturing of innovative cooling and heating solutions, focusing on solid-state technology. Founded in 2008 and based in Durham, North Carolina, the company develops thermoelectric devices and heat pumps that replace traditional compressor technology in various applications. Its products are utilized for electronics cooling in sectors such as optoelectronics and high-performance computing, as well as in healthcare, residential, and commercial refrigeration. Phononic's thermoelectric chips, made from bismuth telluride, offer sustainable and efficient temperature control without the use of toxic refrigerants, making them suitable for industries that require precise temperature management while reducing energy consumption. The company's approach aims to deliver smart and sustainable solutions for diverse climate control needs.

Omniox is a biopharmaceutical company focused on developing innovative treatments for hypoxic diseases, which occur when tissues receive insufficient oxygen. This condition is linked to serious health issues, including various cancers and cardiovascular diseases. The company utilizes a proprietary protein-based platform technology known as H-NOX, which is designed to deliver oxygen and nitric oxide directly to hypoxic tissues. By specifically targeting these areas, Omniox aims to restore normal tissue function, potentially improving patient outcomes and offering new therapeutic options. Through its work, Omniox seeks to advance oxygen-based therapies that address the challenges posed by diseases associated with low oxygen levels.

Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.

AirStrip Technologies, Inc. is a provider of technology solutions designed to enhance collaboration among caregivers and improve patient care. Its flagship product, AirStrip ONE, is a data- and vendor-agnostic platform that enables clinicians to access critical patient information, including real-time waveform data, from various hospital monitoring systems on their mobile devices. This platform facilitates communication and data sharing across the healthcare continuum, helping to break down barriers related to geography, technology, and workflows. Additionally, AirStrip offers Accelerator Services, which provide essential business intelligence to support clinical interoperability. The company's solutions address a range of healthcare challenges, including digital ECG snippets, alarm management, remote patient monitoring, and maternal/fetal data management. Founded in 2004 and headquartered in San Antonio, Texas, AirStrip serves a diverse clientele that includes health systems, healthcare providers, and information technology clients within the healthcare sector.

Kymab Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of human monoclonal antibody therapeutics. Utilizing its proprietary Kymouse platform, Kymab captures the diversity of the human immune system's B lymphocyte component to generate biopharmaceuticals targeting both established and novel drug targets. The company's therapeutic focus spans immuno-oncology, immunology, and other opportunistic areas. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to enhance its research and development efforts. Founded in 2009, Kymab continues to advance its pipeline of monoclonal antibody candidates aimed at addressing significant medical needs.

The mission of Integrated Diagnostics is to leverage powerful emerging technologies in the development of diagnostic products that enable physicians and patients to manage complex and important diseases such as cancer, diabetes and Alzheimer's through blood tests that can monitor tens to hundreds of disease markers simultaneously. The company plans to develop a pipeline of game-changing diagnostic products that enable the diagnosis and prognosis of a variety of diseases. The company is based on the concept of a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes and other molecules.

Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, specializing in the development of medical treatments for atrial fibrillation (AF), the most common type of cardiac arrhythmia. Founded in 2011, the company focuses on creating SK channel inhibitors, which are designed to be safe and tolerable options for patients. These drugs work by inhibiting specific ion channels in heart cells that are crucial for generating the electrical signals that regulate the heart's rhythm. Acesion Pharma aims to provide effective chronic treatments that prevent the recurrence of AF and help maintain a normal heart rhythm.

Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company based in Malvern, Pennsylvania, established in 2010. The company specializes in the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections, including challenging conditions caused by pathogens such as MRSA, Pseudomonas, and Salmonella. Venatorx has developed a robust in-house research and development organization that has filed over 100 patents across various research initiatives. The company has received substantial funding from notable organizations, including the National Institute of Allergy and Infectious Diseases, Wellcome Trust, and the Biomedical Advanced Research and Development Authority, as well as private equity investments from firms like Versant Ventures and Abingworth. This support highlights Venatorx's commitment to addressing critical public health challenges related to resistant infections.

Treventis Corporation is an early-stage biotechnology company specializing in the treatment of diseases linked to protein misfolding, including Alzheimer's, Parkinson's, and Huntington's diseases. The company is focused on developing small molecule drugs that can penetrate the brain and neutralize misfolded proteins, with the goal of halting the progression of Alzheimer's disease and other dementias. Treventis is also working on companion diagnostics that facilitate the early detection of Alzheimer's, enabling timely intervention to minimize neuronal loss. Their innovative approach aims to block amyloid toxicity while minimizing side effects for patients.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, specializing in tissue regenerative implants for patients with knee injuries. Founded in 2008 by Dr. Nick Skaer and Professor Oliver Kessler, the company leverages silk technology developed at Oxford University to create innovative solutions for cartilage and meniscus repair. Its primary products include FibroFix, a biomaterial designed to replicate human knee cartilage; FibroFix Meniscus, which focuses on repairing and regenerating meniscal cartilage; and FibroFix Cartilage, aimed at treating articular cartilage damage. The technology behind these products was originally developed at Oxford Biomaterials Ltd., where Dr. Skaer played a significant role in advancing the FibroFix technology platform before securing exclusive licenses for its application in cartilage and bone repair.

Trino is a drug discovery and early drug development company focused on anti-inflammatory therapeutics. The company is developing drug candidates from a novel, proprietary, class of drugs based on indane dimers derived from a Taiwanese fern. Its lead candidate is a potential first-in-class drug for the treatment of inflammatory bowel disease (IBD), which could be used in both ulcerative colitis (UC) and Crohn’s disease (CD). Trino’s drug class also offers promising candidates with a broad anti-inflammatory activity that could be suitable for applications in dermatology, pulmonary and auto-immune disease.

Canbex Therapeutics, Ltd. is a London-based company founded in 2005 that focuses on developing peripherally-acting cannabinoid agonists aimed at treating spasticity associated with multiple sclerosis and other neurodegenerative diseases. Spasticity is characterized by involuntary spasms and stiffness, which can significantly impact the quality of life for affected individuals. Canbex Therapeutics is committed to enhancing the treatment landscape for this debilitating symptom, striving to set a new standard for managing spasticity and improving patient outcomes in those suffering from these serious conditions.

Antabio SAS is a biopharmaceutical company based in Labège, France, focused on developing drugs to combat antibiotic-resistant bacterial infections. Established in 2009, the company specializes in creating inhibitors that target bacterial metalloenzymes to restore the efficacy of existing antibiotics against critical pathogens. Among its key developments are a Metallo Beta-Lactamase inhibitor designed to enhance carbapenem treatment, a Serine Beta-Lactamase inhibitor with broad coverage against key enzymes, and Pseudomonas Elastase inhibitors, which aim to reduce the frequency and severity of exacerbations in patients with Pseudomonas infections. Antabio's innovative approach addresses significant unmet medical needs in the fight against nosocomial infections, particularly those caused by drug-resistant bacteria.

Haemostatix Ltd. is a biotechnology company based in Nottingham, United Kingdom, founded in 2003 as a spin-out from the University of Leicester. The company specializes in a peptide-based platform technology designed to develop innovative products for managing surgical bleeding, with potential applications in tissue repair and regenerative medicine. Its flagship product, PeproStat, is a topical coagulant that can be applied directly to wounds during surgery to effectively control bleeding. The technology is based on a specific peptide sequence that binds to fibrinogen, a crucial protein in clot formation, and can be adapted to various solid supports or soluble carriers. This platform underpins a promising pipeline of first-in-class products aimed at treating different forms of bleeding, including those associated with surgery, trauma, and leukaemia. As of 2016, Haemostatix operates as a subsidiary of Ergomed plc.

Summit Therapeutics Inc. is a biopharmaceutical company engaged in the discovery, development, and commercialization of innovative antibiotics aimed at treating serious infectious diseases. The company specializes in Clostridium difficile infection (CDI) and is advancing its lead candidate, ridinilazole, an orally administered small molecule antibiotic currently in Phase III clinical trials. Additionally, Summit is developing the DDS-01 series to combat infections caused by Neisseria gonorrhoeae and the DDS-04 series to address Enterobacteriaceae infections. Founded in 2003 and headquartered in Cambridge, Massachusetts, Summit Therapeutics focuses on creating new standards of care that benefit patients while delivering value to payors and healthcare providers across the United States and Europe.

AirStrip Technologies, Inc. is a provider of technology solutions designed to enhance collaboration among caregivers and improve patient care. Its flagship product, AirStrip ONE, is a data- and vendor-agnostic platform that enables clinicians to access critical patient information, including real-time waveform data, from various hospital monitoring systems on their mobile devices. This platform facilitates communication and data sharing across the healthcare continuum, helping to break down barriers related to geography, technology, and workflows. Additionally, AirStrip offers Accelerator Services, which provide essential business intelligence to support clinical interoperability. The company's solutions address a range of healthcare challenges, including digital ECG snippets, alarm management, remote patient monitoring, and maternal/fetal data management. Founded in 2004 and headquartered in San Antonio, Texas, AirStrip serves a diverse clientele that includes health systems, healthcare providers, and information technology clients within the healthcare sector.

Siluria Technologies is a materials innovation company solving global challenges for partners in the natural gas, chemicals and fuel industries. Integrating nanotechnology, biotechnology and chemical engineering, Siluria has developed a solution to the grand challenge of efficient manufacturing: the ability to produce chemicals and fuels from a cheaper, more abundant resource than oil. The company's economically superior, energy-efficient platform converts natural gas into the same materials manufactured today using current industry infrastructure. Siluria's world-class R&D and engineering teams are rapidly commercializing the company's technology to pilot-scale production in close dialogue with the world's largest chemical and fuel companies.Siluria's backers include Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and Presidio Ventures.

Cell Medica is a cell therapy company working on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy. This technique involves harnessing and enhancing the power of the human immune system to fight disease. Based on a number of academic studies, there is strong evidence that cellular immunotherapy can be used in a safe and effective manner to treat diseases ranging from infections to cancer. Cell Medica is both an R&D company developing new forms of cell therapies and a cell production/processing company providing clinical-grade cell formulations to hospitals for the treatment of patients.

Castlight Health is dedicated to simplifying the healthcare experience and promoting healthier, more productive lives. Its health navigation platform integrates with various health vendors, benefits resources, and plan designs, creating a comprehensive application that addresses diverse health needs. By tailoring guidance to individual profiles, Castlight assists users, whether they are healthy, managing chronic conditions, or seeking medical care, in accessing optimal resources. The company aims to help organizations manage rising healthcare costs and enhance the value of their benefits investments. Since its inception, Castlight has introduced innovative solutions such as data-driven price transparency tools and a consumer-friendly wellbeing platform. Currently, it serves millions of users and partners with numerous large employers, positioning itself as a key player in the healthcare sector. Castlight is headquartered in San Francisco.

Sapphire Energy, Inc. is a San Diego-based company specializing in the production of renewable solutions from algae, aiming to innovate the energy and petrochemical industries through its Green Crude initiative. Founded in 2007, the company utilizes sunlight, carbon dioxide, non-potable water, non-arable land, and specific strains of algae in outdoor ponds to generate biomass. This biomass can be transformed into high-value products, including oils, aquaculture and animal feeds, and fuels. Unlike traditional biofuels, Sapphire's processes are not reliant on food crops or valuable farmland, do not consume potable water, and yield products compatible with existing infrastructure. The company operates a research and development facility in Las Cruces, New Mexico, and is developing an integrated algal bio refinery in Columbus, New Mexico, to enhance its production capabilities.

The mission of Integrated Diagnostics is to leverage powerful emerging technologies in the development of diagnostic products that enable physicians and patients to manage complex and important diseases such as cancer, diabetes and Alzheimer's through blood tests that can monitor tens to hundreds of disease markers simultaneously. The company plans to develop a pipeline of game-changing diagnostic products that enable the diagnosis and prognosis of a variety of diseases. The company is based on the concept of a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes and other molecules.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for rare disorders and oncology. Notably, it offers Translarna and Emflaza for treating nonsense mutation Duchenne muscular dystrophy in ambulatory patients. The company is advancing several clinical programs, including Translarna for nonsense mutation aniridia and Dravet syndrome/CDKL5, as well as RG7916 and RO7034067 for spinal muscular atrophy. Additionally, PTC Therapeutics is developing PTC596 and PTC299, a small molecule targeting cancer treatment, and a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. Collaborations with various organizations, including F. Hoffman-La Roche and the Spinal Muscular Atrophy Foundation, enhance its research and commercialization efforts. Founded in 1998, PTC Therapeutics is headquartered in South Plainfield, New Jersey.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, the company aims to enhance patient comfort and therapeutic outcomes with its innovative, high-resolution, and MRI-compatible DBS system. Sapiens specializes in developing a comprehensive DBS solution that includes navigation and steering software, as well as implants specifically designed for patients with Parkinson's disease. With offices in Eindhoven, the Netherlands, and Munich, Germany, Sapiens leverages patented technologies to deliver effective and precise treatment options for individuals suffering from this neurological condition.

Sapiens Decision is a prominent provider of software solutions tailored for the insurance industry, with an expanding focus on the financial services sector. The company offers a comprehensive range of software and professional services, addressing various needs within property and casualty, life, pension and annuities, reinsurance, and other financial markets. Sapiens also specializes in decision modeling and business decision management software, catering to both insurance and financial clients. With over 30 years of experience, Sapiens serves more than 200 financial services organizations globally. The company employs approximately 1,700 professionals and operates through fully-owned subsidiaries in North America, Europe, the Middle East, Africa, and the Asia-Pacific region.

Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.

Siluria Technologies is a materials innovation company solving global challenges for partners in the natural gas, chemicals and fuel industries. Integrating nanotechnology, biotechnology and chemical engineering, Siluria has developed a solution to the grand challenge of efficient manufacturing: the ability to produce chemicals and fuels from a cheaper, more abundant resource than oil. The company's economically superior, energy-efficient platform converts natural gas into the same materials manufactured today using current industry infrastructure. Siluria's world-class R&D and engineering teams are rapidly commercializing the company's technology to pilot-scale production in close dialogue with the world's largest chemical and fuel companies.Siluria's backers include Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and Presidio Ventures.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

Canbex Therapeutics, Ltd. is a London-based company founded in 2005 that focuses on developing peripherally-acting cannabinoid agonists aimed at treating spasticity associated with multiple sclerosis and other neurodegenerative diseases. Spasticity is characterized by involuntary spasms and stiffness, which can significantly impact the quality of life for affected individuals. Canbex Therapeutics is committed to enhancing the treatment landscape for this debilitating symptom, striving to set a new standard for managing spasticity and improving patient outcomes in those suffering from these serious conditions.

Beyond Oblivion is a music and technology company founded in 2008 by its CEO, Adam Kidron. Its principle shareholders are Wellcome Trust, News Corporation, Allen & Company, Intertrust Technologies Corporation, and Adam Kidron. Beyond Oblivion's first go-to-market product is boinc. boinc is a magnetic and social music service that distributes a vast legal music library from a cloud (supplied by majors, independents, and artists the world over), and embeds the right to download and PLAY IT ALL within devices like PCs, tablets, autos and smartphones. boinc replaces paid-download, paid subscription, and advertiser-supported services with an inexpensive one-time, lifetime-of-device usage fee - paying copyright owners a micro-royalty per play, no matter if the original file were legally or illegally downloaded.

Wonga.com offers small, short-term cash advances to consumers in the UK through an online platform. Utilizing advanced risk assessment and decision-making technology, the company provides automated lending decisions that aim to be responsible and efficient. Customers can select the desired loan amount, up to £750, and the repayment period, ranging from five to 30 days, using interactive tools on the website. Wonga's automated loan processing enables rapid cash deposits, often within minutes, providing a faster alternative to traditional credit sources. The service is designed for occasional use in response to cash emergencies, helping customers avoid potential pitfalls such as unauthorized overdrafts or high bank fees associated with bounced checks. Wonga's innovative approach to lending has garnered recognition through various awards, highlighting its contribution to the financial technology sector.

Haemostatix Ltd. is a biotechnology company based in Nottingham, United Kingdom, founded in 2003 as a spin-out from the University of Leicester. The company specializes in a peptide-based platform technology designed to develop innovative products for managing surgical bleeding, with potential applications in tissue repair and regenerative medicine. Its flagship product, PeproStat, is a topical coagulant that can be applied directly to wounds during surgery to effectively control bleeding. The technology is based on a specific peptide sequence that binds to fibrinogen, a crucial protein in clot formation, and can be adapted to various solid supports or soluble carriers. This platform underpins a promising pipeline of first-in-class products aimed at treating different forms of bleeding, including those associated with surgery, trauma, and leukaemia. As of 2016, Haemostatix operates as a subsidiary of Ergomed plc.

ProteinSimple is part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH). They rethinking protein tools and helping thousands of researchers around the world resolve their protein analysis problems so they can reveal new insight into proteins and their role in disease. Their wide-ranging portfolio of tools includes everything from immunoassay systems that quantify protein expression to systems that probe the structure and purity of protein-based therapeutics.

Kymab Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of human monoclonal antibody therapeutics. Utilizing its proprietary Kymouse platform, Kymab captures the diversity of the human immune system's B lymphocyte component to generate biopharmaceuticals targeting both established and novel drug targets. The company's therapeutic focus spans immuno-oncology, immunology, and other opportunistic areas. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to enhance its research and development efforts. Founded in 2009, Kymab continues to advance its pipeline of monoclonal antibody candidates aimed at addressing significant medical needs.

Castlight Health is dedicated to simplifying the healthcare experience and promoting healthier, more productive lives. Its health navigation platform integrates with various health vendors, benefits resources, and plan designs, creating a comprehensive application that addresses diverse health needs. By tailoring guidance to individual profiles, Castlight assists users, whether they are healthy, managing chronic conditions, or seeking medical care, in accessing optimal resources. The company aims to help organizations manage rising healthcare costs and enhance the value of their benefits investments. Since its inception, Castlight has introduced innovative solutions such as data-driven price transparency tools and a consumer-friendly wellbeing platform. Currently, it serves millions of users and partners with numerous large employers, positioning itself as a key player in the healthcare sector. Castlight is headquartered in San Francisco.

Biota is an Australian company engaged in the discovery, development, and commercialization of anti-infective drugs, focusing primarily on respiratory diseases, including influenza. The company developed zanamivir, marketed as Relenza, to treat seasonal influenza and has also produced nucleoside analogues for hepatitis C, which were licensed to Boehringer Ingelheim. Biota is actively involved in clinical trials for its lead compound targeting human rhinovirus infections, especially in patients with compromised respiratory or immune systems. Additionally, the company collaborates with Daiichi Sankyo to develop second-generation antiviral treatments. Beyond its pharmaceutical endeavors, Biota also provides environmental services, working with businesses and municipal governments alongside local farmers. Their services include biodiversity protection, ecological engineering, agroecology, and reforestation, with a project design process that assesses client needs and involves farmer selection, project implementation, and ongoing monitoring to enhance soil carbon stocks and combat climate change.

Achaogen, Inc. is a biopharmaceutical company focused on developing antibacterial agents to combat multi-drug resistant (MDR) gram-negative infections. The company's primary product, plazomicin, is designed to treat serious bacterial infections caused by MDR enterobacteriaceae, particularly carbapenem-resistant strains. Additionally, Achaogen is working on C-Scape, an orally-administered combination therapy targeting infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established several collaboration agreements, including partnerships with Thermo Fisher Scientific for assay development, and Ionis Pharmaceuticals for the advancement of aminoglycoside antibacterial compounds. The company generates revenue primarily through government contracts for research and development. Founded in 2002 and based in South San Francisco, California, Achaogen filed for Chapter 11 bankruptcy in April 2019, transitioning to a liquidation plan in May 2020.

Mintaka Foundation is finding simple health solutions for developing countries using advanced technology.

Summit Therapeutics Inc. is a biopharmaceutical company engaged in the discovery, development, and commercialization of innovative antibiotics aimed at treating serious infectious diseases. The company specializes in Clostridium difficile infection (CDI) and is advancing its lead candidate, ridinilazole, an orally administered small molecule antibiotic currently in Phase III clinical trials. Additionally, Summit is developing the DDS-01 series to combat infections caused by Neisseria gonorrhoeae and the DDS-04 series to address Enterobacteriaceae infections. Founded in 2003 and headquartered in Cambridge, Massachusetts, Summit Therapeutics focuses on creating new standards of care that benefit patients while delivering value to payors and healthcare providers across the United States and Europe.

Oxagen Limited, a biopharmaceutical company, develops and commercializes anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhinoconjunctivitis. Its drug programs target the CRTH2 receptor that initiates and maintains allergic conditions. The company develops a pipeline of small molecule drugs. It serves customers in the United Kingdom, Russia, CIS countries, and internationally. Oxagen Limited was incorporated in 1996 and is based in London, United Kingdom.

Nabriva Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious bacterial infections. The company's lead product, lefamulin, is a semi-synthetic pleuromutilin antibiotic designed to treat community-acquired bacterial pneumonia and acute bacterial skin infections. It is currently undergoing clinical trials for additional applications, including pediatric infections, sexually transmitted infections, osteomyelitis, and prosthetic joint infections. Nabriva is also advancing CONTEPO, an epoxide antibiotic aimed at treating complicated urinary tract infections, and it is in clinical trials for peri-operative prophylaxis. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva Therapeutics has evolved from its earlier identity as a research institute focused on antibiotic development.

The mission of Integrated Diagnostics is to leverage powerful emerging technologies in the development of diagnostic products that enable physicians and patients to manage complex and important diseases such as cancer, diabetes and Alzheimer's through blood tests that can monitor tens to hundreds of disease markers simultaneously. The company plans to develop a pipeline of game-changing diagnostic products that enable the diagnosis and prognosis of a variety of diseases. The company is based on the concept of a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes and other molecules.

Pacific Biosciences designs, develops, and manufactures advanced sequencing systems that address complex genetic challenges. Utilizing single molecule real-time (SMRT) sequencing technology, it enables the real-time detection of biological processes at the single-molecule level. The company offers products such as the PacBio RS II and Sequel Systems, which are capable of conducting, monitoring, and analyzing biochemical reactions in real time. In addition to sequencing systems, Pacific Biosciences provides consumables like SMRT cells and various reagent kits essential for template preparation, binding, and sequencing. Its diverse customer base includes research institutions, commercial laboratories, genome centers, and various sectors such as pharmaceuticals and agriculture. The company markets its products through a direct sales force in North America and Europe, along with distribution partners in Asia, the Middle East, and Latin America. Founded in 2000, Pacific Biosciences is headquartered in Menlo Park, California.

Chroma Therapeutics Ltd. is a biotechnology company based in Abingdon, United Kingdom, specializing in the discovery and development of novel small molecule drugs targeting cancer and inflammatory disorders. Founded in 2000, Chroma leverages chromatin biology and innovative cell accumulation techniques to create its product pipeline. Key products include Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor designed for cancer treatment; and CHR-2845, focused on hematological malignancies. The company is recognized for its systematic assembly of intellectual property in chromatin biology and has established a strong network of academic collaborations to enhance its research and development efforts.

VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

ProteinSimple is part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH). They rethinking protein tools and helping thousands of researchers around the world resolve their protein analysis problems so they can reveal new insight into proteins and their role in disease. Their wide-ranging portfolio of tools includes everything from immunoassay systems that quantify protein expression to systems that probe the structure and purity of protein-based therapeutics.

Phico Therapeutics Limited operates as a biotechnology company that primarily focuses on developing antibiotics to overcome antibacterial resistance. Its SASPject platform delivers anti-bacterial proteins, such as small acid-soluble spore proteins to selected bacterial species using targetable non-delivery vehicles. The company’s portfolio includes SASPject PT3, an antibiotic against Pseudomonas aeruginosa; SASPject PT4 and SASPject PT5 for systemic use against Klebsiella pneumonia and Escherichia coli; and SASPject PT1.2 that targets Staphylococcus aureus. Phico Therapeutics Limited was incorporated in 2000 and is based in Bourn, United Kingdom.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, specializing in tissue regenerative implants for patients with knee injuries. Founded in 2008 by Dr. Nick Skaer and Professor Oliver Kessler, the company leverages silk technology developed at Oxford University to create innovative solutions for cartilage and meniscus repair. Its primary products include FibroFix, a biomaterial designed to replicate human knee cartilage; FibroFix Meniscus, which focuses on repairing and regenerating meniscal cartilage; and FibroFix Cartilage, aimed at treating articular cartilage damage. The technology behind these products was originally developed at Oxford Biomaterials Ltd., where Dr. Skaer played a significant role in advancing the FibroFix technology platform before securing exclusive licenses for its application in cartilage and bone repair.

Qwell's goal is to develop a new family of small-molecule drugs, derived from a plant source, that have a potent ability to fight tumors and excess inflammation of skin cells.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

Sapphire Energy, Inc. is a San Diego-based company specializing in the production of renewable solutions from algae, aiming to innovate the energy and petrochemical industries through its Green Crude initiative. Founded in 2007, the company utilizes sunlight, carbon dioxide, non-potable water, non-arable land, and specific strains of algae in outdoor ponds to generate biomass. This biomass can be transformed into high-value products, including oils, aquaculture and animal feeds, and fuels. Unlike traditional biofuels, Sapphire's processes are not reliant on food crops or valuable farmland, do not consume potable water, and yield products compatible with existing infrastructure. The company operates a research and development facility in Las Cruces, New Mexico, and is developing an integrated algal bio refinery in Columbus, New Mexico, to enhance its production capabilities.

Senexis is operates as a small-molecule drug discovery company, engages in discovering compounds for the treatment of ageing-related diseases resulting from the toxicity of amyloid-like proteins. The company offers small molecule inhibitors of amyloid aggregation and toxicity as therapeutic agents to inhibit the pathogenic process of protein misfolding, amyloid-related toxicity, and inflammation.

Endotis discovers, develops, and manufactures cardiovascular therapeutics. The company also discovers and develops small-glyco drugs for applications in thrombosis, oncology, and hematology areas. Its portfolio of products includes EP217609, a neutralizable anti-coagulant for managing extracorporeal blood circulation during open-heart surgery; FondaParinux, an injectable drug for the prevention and treatment of venous thromboembolism; and an oral anti-coagulant for stroke prevention in atrial fibrillation. Endotis was founded in 2003 and is based in Romainville, France.

Novacta Biosystems Ltd, founded in 2003, specializes in the development of biopharmaceuticals aimed at treating bacterial infections, particularly those caused by drug-resistant strains. The company employs a dual business model that combines biocatalysis and microbial pathway engineering services with the discovery and development of novel small peptide molecules known as lantibiotics. These innovative therapies target various bacterial infections, including Clostridium difficile. By leveraging the expertise of GSK's Biotransformation and Natural Products scientific team, Novacta has established a robust infectious disease therapeutic pipeline, focusing on delivering effective anti-infective solutions.

Fovea Pharmaceuticals is a French biopharmaceutical company based in Paris, specializing in the discovery and development of drugs for ocular diseases. Founded in 2005, the company focuses on addressing various eye conditions, including allergic conjunctivitis, diabetic macular edema, and retinitis pigmentosa. Its product portfolio includes FOV1101 Prednisporin for allergic conjunctivitis, a proprietary plasma kallikrein-kinin inhibitor known as FOV2302 for hereditary angioedema, FOV2304 for diabetic macular edema, and FOV2501, an intravitreal formulation targeting retinitis pigmentosa and potentially dry age-related macular degeneration. As of October 30, 2009, Fovea operates as a subsidiary of Sanofi.

Sentinel Oncology Limited, a drug discovery company, develops and commercializes therapeutics to treat cancer. The company develops small molecule approaches to target the microenvironment of solid tumors. Its R&D programs pipeline includes Checkpoint Kinase 1, a protein kinase that activates in response to DNA damage and DNA replication stress; and an approach to treat metastatic breast cancer by developing a drug that inhibits S6K1 and offers treatment options for patients. The company was founded in 2005 and is based in Cambridge, United Kingdom.

Lectus Therapeutics Limited is a UK-based pharmaceutical company dedicated to drug discovery and development, specializing in next-generation ion channel modulators. The company aims to create a robust pipeline of first-in-class therapeutics, primarily targeting pain management and urinary bladder disorders. Utilizing proprietary proteomics technology, Lectus Therapeutics focuses on developing innovative treatments for various conditions, including angina, asthma, and epilepsy, alongside its core areas of interest. Through its commitment to advancing ion channel therapeutics, the company seeks to address unmet medical needs in the pharmaceutical landscape.

Xtera Communications, Inc. was a provider of optical transport solutions, specializing in Raman amplification enabled systems for both terrestrial and submarine networks. Founded in 1998 and headquartered in Allen, Texas, the company served telecommunications service providers, content service providers, enterprises, and government entities globally. Xtera offered a range of products, including un-repeatered and repeatered systems, designed to enhance network reach and capacity. The company focused on creating customized solutions, whether through complete turnkey systems, open architecture designs, or specific product offerings. Xtera's strategic growth included the acquisition of AscenVision, which expanded its product portfolio beyond optical solutions. However, Xtera entered Chapter 11 bankruptcy in November 2016, and its liquidation process began in February 2017, marking the end of its operations.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

Cell Medica is a cell therapy company working on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy. This technique involves harnessing and enhancing the power of the human immune system to fight disease. Based on a number of academic studies, there is strong evidence that cellular immunotherapy can be used in a safe and effective manner to treat diseases ranging from infections to cancer. Cell Medica is both an R&D company developing new forms of cell therapies and a cell production/processing company providing clinical-grade cell formulations to hospitals for the treatment of patients.

Prolysis is an antibacterial drug discovery and development company based in Oxford, UK. We are focused on creating new antibacterial drugs that are urgently needed to treat hospital-acquired and community-associated infections.

Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.

Chroma Therapeutics Ltd. is a biotechnology company based in Abingdon, United Kingdom, specializing in the discovery and development of novel small molecule drugs targeting cancer and inflammatory disorders. Founded in 2000, Chroma leverages chromatin biology and innovative cell accumulation techniques to create its product pipeline. Key products include Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor designed for cancer treatment; and CHR-2845, focused on hematological malignancies. The company is recognized for its systematic assembly of intellectual property in chromatin biology and has established a strong network of academic collaborations to enhance its research and development efforts.